Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity

Obesity (Silver Spring). 2020 May;28(5):870-881. doi: 10.1002/oby.22764. Epub 2020 Mar 18.


Objective: The aim of this study was to explore the dose response of licogliflozin, a dual inhibitor of sodium/glucose cotransporter 1 (SGLT1) and 2 (SGLT2), by evaluating change in body weight in adults with overweight or obesity.

Methods: This dose-response analysis evaluated change in body weight following 24 weeks with four once-daily and twice-daily licogliflozin doses (2.5-150 mg) versus placebo (primary end point). A further 24-week analysis evaluated the efficacy and safety of two once-daily licogliflozin doses in maintaining initial weight reduction.

Results: Licogliflozin once daily or twice daily produced a significant dose-response signal for weight loss versus placebo (P < 0.0001). However, mean adjusted percent changes in body weight after 24 weeks were modest, ranging from -0.45% to -3.83% (in the 50 mg twice daily group [95% CI: -5.26% to -2.48%]; n = 75). Responder analysis of ≥ 5% weight loss at week 24 revealed significant differences versus placebo, which were most pronounced with highest doses of 50 mg twice daily (45.3%) and 150 mg once daily (42.9%) (both P < 0.01). While weight loss was greater at higher doses, gastrointestinal adverse events were also more frequent. The 50-mg once-daily dose had perhaps the best balance between efficacy and tolerability.

Conclusions: Licogliflozin produced significant reductions in body weight versus placebo. However, the magnitude of weight reduction was modest.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anhydrides / pharmacology
  • Anhydrides / therapeutic use*
  • Body Weight / drug effects*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obesity / drug therapy*
  • Overweight / drug therapy*
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
  • Sorbitol / analogs & derivatives*
  • Sorbitol / pharmacology
  • Sorbitol / therapeutic use
  • Weight Loss / drug effects*
  • Young Adult


  • Anhydrides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sorbitol
  • licogliflozin